Suchergebnisse - "Zhuang, Zhixiang"

PubPharm (82)

1

DDX24 promotes tumor progression by mediating hexokinase-1 induced glycolysis in gastric cancer

enthalten in: Cellular signalling | 2024

von Ni, Y. | Zhuang, Z.

2

Causal Relationships of Chronic Constipation and Irritable Bowel Syndrome with Digestive Tract Cancers : A Mendelian Randomization Study

enthalten in: Recent patents on anti-cancer drug discovery | 2024

von Fan, R. | Zhang, J. | Shen, J. | +3

3

Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors : A multicenter phase 2 study

enthalten in: Cell reports. Medicine | 2023

von Zhang, B. | Song, Y. | Luo, S. | +26

4

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer : The ORIENT-16 Randomized Clinical Trial

enthalten in: JAMA | 2023

von Xu, J. | Jiang, H. | Pan, Y. | +66

CommentIn: JAMA. 2024 Apr 16;331(15):1333-1334. - PMID 38512227

5

Novel Method for Detection of PIK3CA Mutations in Circulating Tumor DNA of Patients with Colorectal Cancer

enthalten in: Applied biochemistry and biotechnology | 2023

von Pu, W. | Wang, F. | Li, K. | +6

6

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

7

Peripheral CD4+CD25hiCD127low regulatory T cells are increased in patients with gastrointestinal cancer

enthalten in: BMC gastroenterology | 2023

von Qiu, J. | Shi, W. | Zhang, J. | +3

8

Novel Method for Detection of PIK3CA Mutations in Circulating Tumor DNA of Patients with Colorectal Cancer

enthalten in: Applied biochemistry and biotechnology | 2023

von Pu, W. | Wang, F. | Li, K. | +6

9

Retracted] MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis

enthalten in: International journal of molecular medicine | 2023

von Chen, L. | Chen, Q. | Wu, Y. | +3

RetractionOf: Int J Mol Med. 2021 May;47(5):. - PMID 33649808

10

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

enthalten in: BMC medicine | 2023

von Shi, Y. | Zhou, J. | Zhao, Y. | +13

1
2
3
4
5
6
7
8
9
Nächster »
[9]